Tg Therapeutics (TGTX) Other Non-Current Liabilities (2010 - 2026)

Tg Therapeutics' Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $777000.0 for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 64.08% year-over-year to $777000.0 in Q1 2026; TTM through Mar 2026 was $777000.0, a 64.08% decrease from a year earlier, with the FY2025 full-year figure at $2.1 million, down 44.56% from the prior year.
• Other Non-Current Liabilities slipped to $777000.0 in Q1 2026 per TGTX's latest filing, from $2.1 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $3.8 million in Q4 2024 and bottomed at $243000.0 in Q4 2022.
• The 5-year median for Other Non-Current Liabilities is $2.2 million (2025), against an average of $2.1 million.
• Across the five-year window, Other Non-Current Liabilities surged 961.62% in 2024 and slumped 64.08% in 2026, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $243000.0 in 2022, then jumped by 46.91% to $357000.0 in 2023, then jumped by 961.62% to $3.8 million in 2024, then plunged by 44.56% to $2.1 million in 2025, then tumbled by 63.02% to $777000.0 in 2026.
• Per Business Quant, the three latest TGTX Other Non-Current Liabilities figures stand at $777000.0 (Q1 2026), $2.1 million (Q4 2025), and $2.0 million (Q3 2025).